PAVmed Inc. reported Q2 2026 results highlighting progress across its subsidiaries: Veris Health advanced commercial engagement and development of an implantable physiological monitor targeting early 2027 FDA submission; Lucid Diagnostics secured its first lab benefit manager coverage for the EsoGuard test and reported $1.5 million revenue from 2,770 tests; and PAVmed's medical device portfolio, including PortIO and Octeris, reached key development milestones. The company posted a GAAP net loss of $5.5 million but improved cash position to $3.8 million. Upcoming plans include FDA pre-submission meetings and clinical validation studies, supporting PAVmed's growth in medical technology and diagnostics.
Synopsys shares have fallen 15.45% this year despite strong fundamentals, including a 42.4% revenue increase and raised 2026 guidance. The company benefits from AI demand in silicon design and engineering simulation, with a price target of $496.97 im...
McDonald's has been upgraded to a Buy rating due to its attractive valuation that provides a margin of safety despite challenging consumer conditions. The company showed modest sales growth in Q2, strong customer loyalty, and a solid capital return y...
Medicus Pharma has confirmed the 200-microgram dose of its SkinJect patch for further studies targeting Gorlin syndrome, with FDA approval for a pivotal trial underway. The company is also exploring an out-licence for nodular basal cell carcinoma and...
Jim Cramer highlighted large flex-call option purchases in tech and energy stocks like Bloom Energy and Intel, raising questions about the buyer's identity. Weeks earlier, a House disclosure showed Pelosi's spouse had bought shares and call options i...
Five Dividend Kings—Procter & Gamble, Johnson & Johnson, Lowe’s, Emerson Electric, and Genuine Parts Company—are highlighted as top income stocks for retirees due to their decades-long records of annual dividend increases. These companies have mainta...
